Argenx S.E

Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
  • TickerARGX
  • ISINNL0010832176
  • ExchangeEuronext Brussels
  • SectorPharmaceuticals & Biotechnology
  • CountryNetherlands

Analysts

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Alan Vandenberghe ...
  • Bart Cuypers
  • Cedric Duinslaeger
  • Guy Sips
  • Jason Kalamboussis
  • Marcel Achterberg
  • Ruben Devos
  • Sandra Cauwenberghs
  • Wido Jongman
  • Wim Hoste

NEW DYNAMIC TOP PICK LIST 2020

The former Top Pick List and Dynamic Top Pick List are merged into a single New Dynamic Top Pick List. We carefully reviewed our universe looking for solid investment cases, catalysts and attractive valuations: For the Large Caps we selected : AB InBev, Aedifica, Argenx, ASML, Basic-Fit, CFE, D'Ieteren, ING, Orange Belgium and UCB For the Small Caps we retained : Agfa, Fugro, PostNL, Recticel and Sipef

Alan Vandenberghe ...
  • Cedric Duinslaeger
  • Marcel Achterberg
  • Sandra Cauwenberghs
  • Wim Hoste

Morning Note: AD NA, ARGX BB, ASML NA, FUR NA, REC BB

Ahold Delhaize: Massive investment in US supply chain Argenx: Aligning the stars towards the launch of their lives ASML: Higher estimates, TP, Underestimated EUV potential Fugro: Upgraded to Buy and added to our Top Pick list Recticel: Upgrade to BUY, inclusion in our Top Pick List Dynamic Top Pick List: New Dynamic Top Pick List

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Alan Vandenberghe ...
  • Bart Cuypers
  • Cedric Duinslaeger
  • Guy Sips
  • Jason Kalamboussis
  • Marcel Achterberg
  • Ruben Devos
  • Sandra Cauwenberghs
  • Wido Jongman
  • Wim Hoste

NEW DYNAMIC TOP PICK LIST 2020

The former Top Pick List and Dynamic Top Pick List are merged into a single New Dynamic Top Pick List. We carefully reviewed our universe looking for solid investment cases, catalysts and attractive valuations: For the Large Caps we selected : AB InBev, Aedifica, Argenx, ASML, Basic-Fit, CFE, D'Ieteren, ING, Orange Belgium and UCB For the Small Caps we retained : Agfa, Fugro, PostNL, Recticel and Sipef

Alan Vandenberghe ...
  • Cedric Duinslaeger
  • Marcel Achterberg
  • Sandra Cauwenberghs
  • Wim Hoste

Morning Note: AD NA, ARGX BB, ASML NA, FUR NA, REC BB

Ahold Delhaize: Massive investment in US supply chain Argenx: Aligning the stars towards the launch of their lives ASML: Higher estimates, TP, Underestimated EUV potential Fugro: Upgraded to Buy and added to our Top Pick list Recticel: Upgrade to BUY, inclusion in our Top Pick List Dynamic Top Pick List: New Dynamic Top Pick List

Argen X SE: 1 director sold

A director at Argen X SE sold 10,000 shares at 130.210EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

An unfavourable environment weighs on ARGENX SE, which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of ARGENX SE (BE), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date September 6, 2019, the closing price was EUR 118.60 and its target price was estimated at EUR 90.40.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Expert Corporate Governance Service (ECGS)

Argenx - EGM 25 November 2019

In general, Argenx is in compliance with the Dutch regulations relating to the organisation and procedures of the Extraordinary General Meeting. Under ITEM 3, the board of directors seeks approval to amend the Company’s stock option plan ("the Plan"). Although ECGS has no (major) concerns over the proposed amendments, it notes that Plan allows for a (potential) aggregate capital increase of 14.5% of the Company’s issued share capital, which exceeds ECGS’guidelines. In addition, ECGS considers the vesting period for time vesting awards (of between 1 and 3 years) too short. Based on the above, ...

Valérie GASTALDY

Short term view - ARGENX SE : The trend is bullish.

The trend is bullish. Prices are making further progress. The targets are at €82.40 and then €94.80. The break of €58.50 would endanger the trend.

Valérie GASTALDY

Analyse court terme - ARGENX SE : La tendance est haussière.

La tendance est haussière. La progression des cours se poursuit. Les objectifs sont à 82,40 € puis 94,80 €. La rupture de 58,50 € mettrait la tendance en danger.

Valérie GASTALDY

Short term view - ARGENX SE : The background trend is clearly bearish.

The background trend is clearly bearish. Prices are falling again, but the movement has become hesitant. The next support is at €58.50. The background trend would be questioned should prices rise above €94.80.

Valérie GASTALDY

Analyse court terme - ARGENX SE : La tendance de fond est clairement orientée à la baisse.

La tendance de fond est clairement orientée à la baisse. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 58,50 €. La tendance de fond serait remise en cause en cas de franchissement de 94,80 €.

Jérôme VINERIER

Analyse moyen terme - ARGENX SE : La tendance est haussière.

La tendance est haussière. La progression des cours se poursuit. Les objectifs sont à 94,80 € puis 119,80 €. La rupture de 18,80 € mettrait la tendance en danger.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch